Regen BioPharma Signs $10M Equity Line, Sells $125,000 Note
The company netted $112,500 from a discounted note and most of it went to retire old convertible debt.
From the company’s 8-K filing · Read the filing
The reaction, filling in at each close
When it hit
$0.0001
0.0% vs the $0.0001 prior close
Next close
Fills in at the close
After 5 sessions
Pending
After 10 sessions
Pending
The full story, in short
Regen signed a $10,000,000 equity line with Coventry and sold a $125,000 note. Past financing days here averaged a 2.2% decline the next session. Each draw and default conversion adds supply to 2.03 billion shares already outstanding.
The stock last closed at $0.0001 on October 30, 2026, and past reactions do not predict the next one.
What it means for holders
Dilution
Draws under the equity line and any default conversion issue new shares into a base of 2,029,228,670.
Cash
Only $112,500 was netted, and $71,557 of it retired existing convertible debt rather than funding operations.
Risk
A missed payment lets Coventry convert at 90% of the lowest 20 day price, deepening the discount.
1 · What happened
What happened
On October 27, 2026, Regen BioPharma sold Coventry Enterprises a $125,000 unsecured note carrying a $12,500 original issue discount. The company received $112,500 in net proceeds.
The same agreement includes a common stock purchase agreement for up to $10,000,000 over 36 months. Coventry pays 80% of the lowest price the stock trades at over the ten business days before each drawdown notice.
The terms
2 · Why it matters
Why it matters
Most of the note proceeds, $71,557, went to satisfy existing convertible debt and accrued interest, leaving little new money for operations. The note repays in eight monthly installments of $17,187.50 starting six months after funding.
The equity line can only be drawn once an S-1 covering Coventry's resale is effective. With 2,029,228,670 shares outstanding against 5,800,000,000 authorized, each draw adds supply to a heavily diluted base.
What to watch next
- 01Whether an S-1 covering Coventry's resale becomes effective, since draws cannot start before then.
- 02The first $17,187.50 installment, due six months after the October 27, 2026 funding, against the company's reported $239 of cash.
- 03Whether any Event of Default occurs, which would allow conversion at 90% of the lowest 20 day price.
3 · Last time
The last 5 financing days
Regen has had five prior financing event days in our data, the most recent on March 4, 2026. The table shows what each day was about and how the stock moved afterward.
| Date | Event | Next day | 5 days | Recovered |
|---|---|---|---|---|
| Mar 4, 2026 | Debt settled by Regen BioPharma with 77.8M shares issued, diluting holders 36% 8-K | Next day0.0% | 5 days▼ 36.36% | Recoveredflat |
| Feb 13, 2026 | Going concern doubt, heavy dilution and ineffective controls noted by Regen BioPharma 10-Q | Next day0.0% | 5 days▼ 21.43% | Recoveredflat |
| Feb 2, 2026 | Regen BioPharma issues shares to retire debt and bring in capital 8-K | Next day▼ 14.04% | 5 days▼ 36.84% | Recoverednot in 60 |
| Jan 21, 2026 | Regen BioPharma declares dividend on preferred stock for all shareholders 8-K | Next day▲ 16.67% | 5 days▲ 16.67% | Recoveredfaded in 8 |
| Jan 8, 2026 | Going concern flagged as Regen BioPharma files $450K Reg A at deep discount 1-A POS | Next day▼ 13.58% | 5 days▼ 33.33% | Recovered11 sessions |
Across those five days the stock averaged a 2.2% decline the next session, and all five sat below their starting level ten sessions later.
How it unfolded
The story so far
The timeline covers the past 180 days of Regen filings, ending with this 8-K.
Insiders
Our insider data shows no open market buys or sells in the 90 days before this event. No open market buys appear in our data at all, and the data carries no start date.
Not financial advice. Past reactions don’t predict the next one. Figures come from the filing and from daily closing prices.